Abstract is: Anne-Lise Børresen-Dale (born 3 July 1946 in Molde) is a Norwegian biochemist. She is a senior scientist at Oslo University Hospital and Professor of molecular tumor biology at the University of Oslo. She received the 2002 Nordic Medical Prize.In 2015 she received the Fritjof Nansen medal and award for Outstanding Research from the Norwegian Academy of Science and Letters, and in 2017 she was appointed to Commander of the Royal Norwegian St. Olavs Order by the King of Norway. She holds an M.Sc. in biochemistry from NTNU (1970), a D.Sc. in medical biochemical genetics from the University of Oslo (1978) and was awarded full professor competence in gene technology in 1987. She was employed at the Institute of Medical Genetics at the University of Oslo from 1970 as a research assistant, research fellow, senior research fellow and head of section. From 1987 she was a senior scientist at the Department of Genetics at the Norwegian Radium Hospital, and since 1999 she has also been head of department. She has additionally been Professor of molecular tumor biology at the University of Oslo since 1992.
| human | Q5 |
| P2287 | CRIStin ID | 22158 |
| P2671 | Google Knowledge Graph ID | /g/1234hl1n |
| P856 | official website | http://ous-research.no/borresen/ |
| P2038 | ResearchGate profile ID | Anne-Lise_Borresen-Dale |
| P4342 | Store norske leksikon ID | Anne-Lise_Børresen-Dale |
| P214 | VIAF ID | 5408149068456065730009 |
| P7859 | WorldCat Identities ID (superseded) | viaf-5408149068456065730009 |
| P166 | award received | King Olav V's Prize for Cancer Research | Q11981638 |
| University of Oslo Research Prize | Q17773361 | ||
| the Norwegian Research Council Award for Outstanding Research | Q18637028 | ||
| Fridtjof Nansen Award of Excellence, Mathematics-Natural sciences class | Q18757335 | ||
| Nordic Medical Prize | Q21294922 | ||
| P27 | country of citizenship | Norway | Q20 |
| P108 | employer | University of Oslo | Q486156 |
| P734 | family name | Børresen-Dale | Q55314666 |
| Børresen-Dale | Q55314666 | ||
| Børresen-Dale | Q55314666 | ||
| P735 | given name | Anne-Lise | Q18199016 |
| Anne-Lise | Q18199016 | ||
| P463 | member of | Royal Norwegian Society of Sciences and Letters | Q1201052 |
| Norwegian Academy of Science and Letters | Q1423356 | ||
| P106 | occupation | professor | Q121594 |
| researcher | Q1650915 | ||
| P21 | sex or gender | female | Q6581072 |
| P26 | spouse | Jon Dale | Q34187491 |
| Q36016386 | 11q13 is a susceptibility locus for hormone receptor positive breast cancer |
| Q35871567 | 19p13.1 is a triple-negative-specific breast cancer susceptibility locus |
| Q33848895 | 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy |
| Q58048741 | A TP53 mutation detected in cells established from an osteosarcoma, but not in the retinoblastoma of a patient with bilateral retinoblastoma and multiple primary osteosarcomas |
| Q35049524 | A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers |
| Q42590677 | A common BRCA1 mutation in Norwegian breast and ovarian cancer families? |
| Q70584973 | A comparative study of serum amyloid a protein (SAA) from mink and man |
| Q81238446 | A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients |
| Q38476057 | A comparison of different modes for the detection of p53 protein accumulation. A study of bladder cancer |
| Q37619303 | A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium |
| Q40079197 | A linkage study of rabbit serum high density lipoprotein (HDL) allotypes |
| Q37229749 | A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide |
| Q92711687 | A network analysis to identify mediators of germline-driven differences in breast cancer prognosis |
| Q35870483 | A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients |
| Q74340214 | A rare CYP19 (aromatase) variant may increase the risk of breast cancer |
| Q40102629 | A retroviral vector for siRNA expression in mammalian cells |
| Q73436948 | A screening for BRCA1 mutations in breast and breast-ovarian cancer families from the Stockholm region |
| Q36420092 | A segregation analysis of testicular cancer based on Norwegian and Swedish families |
| Q53651538 | A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. |
| Q31094481 | A supervised approach for identifying discriminating genotype patterns and its application to breast cancer data |
| Q28394747 | A systematic comparison of copy number alterations in four types of female cancer |
| Q34854883 | A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer |
| Q72017657 | A twin study of aryl hydrocarbon hydroxylase (AHH) inducibility in cultured lymphocytes |
| Q57421083 | ABCB1 and GST polymorphisms associated with TP53 status in breast cancer |
| Q50062973 | AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth. |
| Q39087778 | AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53. |
| Q40662573 | ATM is not required in somatic hypermutation of VH, but is involved in the introduction of mutations in the switch mu region |
| Q43074862 | ATM mutations in Finnish breast cancer patients |
| Q36671218 | ATM variants 7271T>G and IVS10-6T>G among women with unilateral and bilateral breast cancer |
| Q33254230 | ATM variants and cancer risk in breast cancer patients from Southern Finland |
| Q85655227 | AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma |
| Q38547141 | Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes |
| Q36430949 | Absence of p21 expression is associated with abnormal p53 in human breast carcinomas |
| Q46911784 | Acute myelogenous leukemia in a patient with Li-Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid: a case report |
| Q45945664 | Age, estrogen, and immune response in breast adenocarcinoma and adjacent normal tissue. |
| Q34844477 | Allele diversity of the H-ras-1 variable number of tandem repeats in Norwegian lung cancer patients |
| Q34165640 | Allele-specific copy number analysis of tumors |
| Q34107750 | Allele-specific disparity in breast cancer |
| Q61051652 | Allelic imbalance at chromosome region 11q23 in cervical carcinomas |
| Q34633166 | Alpha fetoprotein is increasing with age in ataxia-telangiectasia |
| Q72393558 | Alterations at chromosome 17 loci in peripheral nerve sheath tumors |
| Q84107402 | Alterations of gene expression in blood cells associated with chronic fatigue in breast cancer survivors |
| Q71456164 | Alterations of p53 and expression of WAF1/p21 in human thyroid tumors |
| Q51122211 | Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Advantages of using constant denaturant gel electrophoresis in mutation detection. |
| Q42145916 | Altered dosage of the sex chromosomes in human testicular cancer: a molecular genetic study |
| Q48173616 | Alternative splicing and mutation status of CHEK2 in stage III breast cancer |
| Q35982008 | Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis |
| Q72224268 | Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis |
| Q28728499 | Amplified loci on chromosomes 8 and 17 predict early relapse in ER-positive breast cancers |
| Q61051653 | An increased risk of cervical intra-epithelial neoplasia grade II-III among human papillomavirus positive patients with theHLA-DQA1*0102-DQB1*0602 haplotype: A population-based case–control study of Norwegian women |
| Q51938455 | Analysis of SNP-expression association matrices. |
| Q51953498 | Analysis of SNP-expression association matrices. |
| Q38471657 | Analysis of p53, p16MTS, p21WAF1 and H-ras in archived bladder tumours from workers exposed to aromatic amines |
| Q44118153 | Analyzing cancer samples with SNP arrays |
| Q73081874 | Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer |
| Q71995579 | Apparent influence of marker genotypes on variation in serum cholesterol in monozygotic twins |
| Q46007046 | Application of microarray analyses to identify genes involved in radiation-induced fibrosis. |
| Q35218520 | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy |
| Q45979098 | Association analysis identifies 65 new breast cancer risk loci. |
| Q73327457 | Association between apolipoprotein E genotypes and cancer risk in patients with acquired immunodeficiency syndrome |
| Q37292963 | Association of ESR1 gene tagging SNPs with breast cancer risk |
| Q60531021 | Association of N-Glycosylation with Breast Carcinoma and Systemic Features Using High-Resolution Quantitative UPLC |
| Q37684672 | Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. |
| Q37268494 | Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry |
| Q52180240 | Association of p53 accumulation with TP53 mutations, loss of heterozygosity at 17p13, and DNA ploidy status in 273 colorectal carcinomas. |
| Q72120298 | Association studies of a polymorphism in the Wilms' tumor 1 locus in Norwegian patients with testicular cancer |
| Q49304286 | Association studies of estrogen receptor polymorphisms in a Norwegian testicular cancer population. |
| Q34384174 | Ataxia-telangiectasia: identification and detection of founder-effect mutations in the ATM gene in ethnic populations |
| Q91117991 | Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences |
| Q60044516 | Author Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors |
| Q61443309 | Author Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors |
| Q43609469 | Automated constant denaturant capillary electrophoresis applied for detection of KRAS exon 1 mutations |
| Q78657550 | BRCA1 mutation screening using restriction endonuclease fingerprinting-single-strand conformation polymorphism in an automated capillary electrophoresis system |
| Q78178731 | BRCA1 screening in patients with a family history of breast or ovarian cancer |
| Q30497664 | BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations |
| Q38914005 | BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer |
| Q37002955 | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers |
| Q79098374 | BUB1infrequently mutated in human breast carcinomas |
| Q36070080 | Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival |
| Q58792549 | Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4 |
| Q82729749 | Blood gene expression profiling of breast cancer survivors experiencing fibrosis |
| Q39451294 | Breast Cancer Molecular Stratification: From Intrinsic Subtypes to Integrative Clusters |
| Q36615065 | Breast and other cancers in 1445 blood relatives of 75 Nordic patients with ataxia telangiectasia |
| Q44031621 | Breast cancer and other cancers in Norwegian families with ataxia-telangiectasia |
| Q37315121 | Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration |
| Q71793997 | Breast cancer information on the web |
| Q64067663 | Breast cancer quantitative proteome and proteogenomic landscape |
| Q35940158 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. |
| Q41133999 | C-erbB-2 protein and neuroendocrine expression in breast carcinomas. |
| Q37121911 | CAMK1D amplification implicated in epithelial-mesenchymal transition in basal-like breast cancer |
| Q30975681 | CGH-Explorer: a program for analysis of array-CGH data |
| Q36449203 | CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer |
| Q77926061 | CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1 |
| Q43903928 | Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries |
| Q28385765 | Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk |
| Q35587062 | Canine Mammary Tumours Are Affected by Frequent Copy Number Aberrations, including Amplification of MYC and Loss of PTEN |
| Q40543849 | Cell-type-specific responses to chemotherapeutics in breast cancer |
| Q44446145 | Characterization of ATM mutations in 41 Nordic families with ataxia telangiectasia |
| Q30433040 | Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study |
| Q46834491 | Characterization of extracellular matrix composition in breast carcinoma. |
| Q45227597 | Chromosome 12 in human testicular cancer: dosage changes and their parental origin |
| Q58048751 | Chromosome 13 alterations in osteosarcoma cell lines derived from a patient with previous retinoblastoma |
| Q61853727 | Chromosome region 8p11-p21: Refined mapping and molecular alterations in breast cancer |
| Q94355849 | Chromosome-wide pharmacogenetics: localisation and linkage disequilibrium of genes coding for ROS metabolism and signalling |
| Q33851725 | Combining gene signatures improves prediction of breast cancer survival |
| Q36600605 | Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk |
| Q46897498 | Common genetic variation in GATA-binding protein 3 and differential susceptibility to breast cancer by estrogen receptor alpha tumor status |
| Q44577591 | Common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer |
| Q31082788 | Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q84239559 | Comparison of globin RNA processing methods for genome-wide transcriptome analysis from whole blood |
| Q55452779 | Comparison of methods for pharmacogenomics: SNaPshot, SNPstream UHT, Nanogen, and RFLP. |
| Q33358940 | Comparison of the Agilent, ROMA/NimbleGen and Illumina platforms for classification of copy number alterations in human breast tumors |
| Q24631412 | Complex landscapes of somatic rearrangement in human breast cancer genomes |
| Q57287587 | Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters |
| Q74243267 | Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screening |
| Q37597399 | Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations |
| Q58048752 | Constant denaturant gel electrophoresis, a modification of denaturing gradient gel electrophoresis, in mutation detection |
| Q36422130 | Contribution of APC and MUTYH mutations to familial adenomatous polyposis susceptibility in Hungary |
| Q34664892 | Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. |
| Q30536665 | Copynumber: Efficient algorithms for single- and multi-track copy number segmentation |
| Q47552766 | Correction to: A systematic comparison of copy number alterations in four types of female cancer |
| Q57278898 | Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q57274743 | Correction: miRNA-mRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast Tumors |
| Q47097548 | Corrigendum to “Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer” [Mol. Oncol. 1 (2007) 160–171]. |
| Q50092775 | Corrigendum: A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers. |
| Q41441599 | Corrigendum: Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells |
| Q38998423 | Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics |
| Q91522794 | DNA copy number motifs are strong and independent predictors of survival in breast cancer |
| Q55019833 | DNA methylation and gene expression patterns in breast cancer progression from in situ carcinoma to invasive carcinoma. |
| Q43700782 | DNA methylation at enhancers identifies distinct breast cancer lineages |
| Q41132483 | DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables |
| Q33816178 | DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response |
| Q37702047 | DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival |
| Q55070800 | DNA methylation status of key cell-cycle regulators such as CDKNA2/p16 and CCNA1 correlates with treatment response to doxorubicin and 5-fluorouracil in locally advanced breast tumors. |
| Q41865824 | DNA polymorphism of the RC8 probe on the X-chromosome. Identification of a new DNA variant with the TaqI enzyme. |
| Q70090987 | DNA polymorphisms in collagen genes: potential use in the study of disease |
| Q61051657 | DQA1 and DQB1 genes in patients with squamous cell carcinoma of the cervix: relationship to human papillomavirus infection and prognosis |
| Q41342922 | Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity |
| Q28473179 | Deciphering normal blood gene expression variation--The NOWAC postgenome study |
| Q53460064 | Deletion of 1p loci and microsatellite instability in colorectal polyps. |
| Q33886925 | Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers |
| Q43591112 | Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors |
| Q54780478 | Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer. |
| Q71859522 | Detection of C-ERBB-2 Related Protein in Sera from Breast Cancer Patients Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour |
| Q35223451 | Detection of DNA variation in cancer |
| Q58048683 | Detection of Mutations by Denaturing Gradient Gel Electrophoresis |
| Q46326907 | Detection of base mutations in genomic DNA using denaturing gradient gel electrophoresis (DGGE) followed by transfer and hybridization with gene-specific probes |
| Q30735617 | Detection of low-frequency mutations in exon 8 of the TP53 gene by constant denaturant capillary electrophoresis (CDCE). |
| Q54536004 | Detection of mutations by single-strand conformation polymorphism (SSCP) analysis and SSCP-hybrid methods. |
| Q57694760 | Detection of point mutations in the p53 gene: Comparison of single-strand conformation polymorphism, constant denaturant gel electrophoresis, and hydroxylamine and osmium tetroxide techniques |
| Q34844430 | Detection of ras gene mutations in human lung cancer: comparison of two screening assays based on the polymerase chain reaction |
| Q57833810 | Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology |
| Q51582637 | Determinants of acquired activated protein C resistance and D-dimer in breast cancer. |
| Q87642873 | Development and validation of a gene profile predicting benefit of postmastectomy radiotherapy in patients with high-risk breast cancer: a study of gene expression in the DBCG82bc cohort |
| Q61054244 | Diet, physical activity and sedentary behaviour in 11–13 year old UK adolescents: The Gateshead Millennium Study |
| Q34358592 | Different gene expression patterns in invasive lobular and ductal carcinomas of the breast |
| Q28217444 | Different genetic components in the Norwegian population revealed by the analysis of mtDNA and Y chromosome polymorphisms |
| Q50915480 | Different genetic pathways to proximal and distal colorectal cancer influenced by sex-related factors. |
| Q34984011 | Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy |
| Q41137386 | Differential expression of miRNAs in pancreatobiliary type of periampullary adenocarcinoma and its associated stroma |
| Q37180537 | Direct Transcriptional Consequences of Somatic Mutation in Breast Cancer |
| Q33257139 | Discovery and validation of breast cancer subtypes |
| Q55449901 | Discovery and validation of breast cancer subtypes. |
| Q50698279 | Disease-specific genomic analysis: identifying the signature of pathologic biology. |
| Q33660965 | Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models |
| Q33244907 | Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms |
| Q42499457 | Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer |
| Q55068058 | E-cadherin and alpha-, beta-, and gamma-catenin protein expression in relation to metastasis in human breast carcinoma. |
| Q34620151 | EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors |
| Q81535508 | ESR1 gene amplification in breast cancer: a common phenomenon? |
| Q24813356 | Early detection of breast cancer based on gene-expression patterns in peripheral blood cells |
| Q67274029 | Effect of gemfibrozil on serum lipid levels |
| Q69023726 | Effect of haptoglobin subtypes on serum lipid levels |
| Q44955068 | Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma |
| Q38323583 | Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer |
| Q73490355 | Enhanced detection of mutations in BRCA1 exon 11 using restriction endonuclease fingerprinting-single-strand conformation polymorphism |
| Q33703690 | Epithelial-stromal interaction 1 (EPSTI1) substitutes for peritumoral fibroblasts in the tumor microenvironment |
| Q57082606 | Erratum: Corrigendum: Signatures of mutational processes in human cancer |
| Q42737815 | Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes |
| Q38319276 | Estrogen receptor beta (ESR2) polymorphisms in familial and sporadic breast cancer |
| Q33236464 | Evaluation of MetriGenix custom 4D arrays applied for detection of breast cancer subtypes |
| Q40346840 | Evaluation of arrayed primer extension for TP53 mutation detection in breast and ovarian carcinomas |
| Q55632064 | Evaluation of the arrayed primer extension resequencing assay for TP53 mutation detection. |
| Q54361261 | Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. |
| Q45326530 | Evidence for a sperm mutation resulting in Duchenne muscular dystrophy |
| Q35064451 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation |
| Q37342144 | Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation |
| Q37349280 | Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway |
| Q27332302 | Excess of miRNA-378a-5p perturbs mitotic fidelity and correlates with breast cancer tumourigenesis in vivo |
| Q31032851 | Experimental validation of data mined single nucleotide polymorphisms from several databases and consecutive dbSNP builds |
| Q35679397 | Expression array technology in the diagnosis and treatment of breast cancer |
| Q34173591 | Expression levels of uridine 5'-diphospho-glucuronosyltransferase genes in breast tissue from healthy women are associated with mammographic density |
| Q54768467 | Expression of E-cadherin and its relation to the p53 protein status in human breast carcinomas. |
| Q35693944 | Expression of an estrogen-regulated variant transcript of the peroxisomal branched chain fatty acid oxidase ACOX2 in breast carcinomas |
| Q77399804 | Expression of cyclin Ds in relation to p53 status in human breast carcinomas |
| Q21245738 | Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters |
| Q94355986 | Expression of wild-type and mutated in breast carcinomas |
| Q46933194 | Expression profiling of breast cancer, influence of tumor genotype and patient genotype. |
| Q46681498 | Expression profiling of peripheral blood cells for early detection. |
| Q34629890 | Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters |
| Q53514045 | Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. |
| Q36134273 | Familial testicular cancer in Norway and southern Sweden |
| Q41824436 | Features of 5'-splice-site efficiency derived from disease-causing mutations and comparative genomics |
| Q54868183 | Fibroblast growth factor receptor 3 (FGFR3) - analyses of the S249C mutation and protein expression in primary cervical carcinomas. |
| Q36111237 | Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus |
| Q35524465 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. |
| Q35063160 | Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk |
| Q39844032 | Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer |
| Q37367871 | Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. |
| Q79359576 | Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53 |
| Q38349207 | Focal amplification and oncogene dependency of GAB2 in breast cancer |
| Q37577925 | Found in transcription: gene expression and other novel blood biomarkers for the early detection of breast cancer |
| Q33892868 | Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer |
| Q72087899 | Frequent loss of 11p13 and 11p15 loci in male germ cell tumours |
| Q35664110 | Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells |
| Q41130119 | Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution |
| Q55652831 | Functional characterization of genes involved in the development of breast cancer. |
| Q36124728 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus |
| Q35206302 | Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer |
| Q53415597 | GSTM1 and NAT2 polymorphisms in operable and non-operable lung cancer patients. |
| Q42439010 | GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas. |
| Q71614141 | Gain of 17q24-qter detected by comparative genomic hybridization in malignant tumors from patients with von Recklinghausen's neurofibromatosis |
| Q36643079 | Gene expression analyses in breast cancer epidemiology: the Norwegian Women and Cancer postgenome cohort study |
| Q24644996 | Gene expression patterns in ovarian carcinomas |
| Q27860709 | Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications |
| Q55601179 | Gene expression profiles and the TP53 mutation status are powerful prognostic markers of breast cancer. |
| Q59565550 | Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer |
| Q35551926 | Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features |
| Q94355873 | Gene expression profiling in whole-blood samples from postmenopausal women exposed to hormone replacement therapy |
| Q36035292 | Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: clinical implications. |
| Q35023605 | Gene expression profiling of human dermal fibroblasts exposed to bleomycin sulphate does not differentiate between radiation sensitive and control patients |
| Q33892902 | Gene expression profiling of peripheral blood cells for early detection of breast cancer |
| Q83222594 | Gene expression profiling of whole-blood samples from women exposed to hormone replacement therapy |
| Q25255387 | Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers |
| Q45912810 | Gene expression studies in radiation-sensitive cell lines. |
| Q36465244 | Genes harbouring susceptibility SNPs are differentially expressed in the breast cancer subtypes |
| Q50222422 | Genetic Haplotyping of Ataxia-telangiectasia Families Localizes the Major Gene to an ∼ 850 kb Region on Chromosome 11q23.1. |
| Q35108760 | Genetic Profiling of Breast Cancer: From Molecular Portraits to Clinical Utility |
| Q72879019 | Genetic alterations in a malignant schwannoma from a patient with neurofibromatosis (NF1) |
| Q72078906 | Genetic alterations of chromosome 17 in human breast carcinoma studied by fluorescence in situ hybridization and molecular DNA techniques |
| Q61051658 | Genetic alterations of the TP53 gene, p53 protein expression and hpv infection in primary cervical carcinomas |
| Q67534085 | Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas |
| Q35993699 | Genetic alterations within the retinoblastoma locus in colorectal carcinomas. Relation to DNA ploidy pattern studied by flow cytometric analysis |
| Q37739048 | Genetic modifiers of CHEK2*1100delC-associated breast cancer risk |
| Q43624306 | Genetic polymorphism and variability of steroid hormone metabolism: connection with risk of developing breast neoplasms |
| Q94355856 | Genetic polymorphisms in the 5' flanking region of glutathione S-transferase P1 affect promoter methylation |
| Q35925620 | Genetic predisposition to ductal carcinoma in situ of the breast |
| Q74119791 | Genetic services in Norway |
| Q28215180 | Genetic susceptibility and environmental estrogen-like compounds |
| Q46944758 | Genetic variants of CYP19 (aromatase) and breast cancer risk |
| Q73540247 | Genetic variants of CYP19 (aromatase) and breast cancer risk |
| Q41914550 | Genetic variation and genetic diseases |
| Q35179897 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study |
| Q34595718 | Genetic variation in putative regulatory loci controlling gene expression in breast cancer |
| Q36422109 | Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium |
| Q30000080 | Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent |
| Q58048737 | Genome Scanning of Human Breast Carcinomas Using Micro- and Minisatellite Core Probes |
| Q41101024 | Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis |
| Q34196315 | Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis |
| Q53485693 | Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients. |
| Q44566389 | Genome-wide association study in breast cancer survivors reveals SNPs associated with gene expression of genes belonging to MHC class I and II. |
| Q64040390 | Genome-wide association study of germline variants and breast cancer-specific mortality |
| Q37678826 | Genomic architecture characterizes tumor progression paths and fate in breast cancer patients |
| Q37712773 | Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer |
| Q36303896 | Genomics in breast cancer-therapeutic implications |
| Q72176950 | Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls |
| Q37109203 | Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein |
| Q61051646 | Germline glutathione S-transferase variants in breast cancer: Relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy |
| Q72377569 | Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma |
| Q68097060 | Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms |
| Q39027048 | Global gene expression analysis reveals a link between NDRG1 and vesicle transport |
| Q35108398 | Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer |
| Q37671122 | Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression |
| Q39042751 | Glycan-related gene expression signatures in breast cancer subtypes; relation to survival |
| Q46944833 | HER-2 activation and TP53 inactivation as predictors of survival in breast cancer |
| Q45348736 | HLA antigens and cervical carcinoma |
| Q48134701 | HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures |
| Q43637601 | Ha-ras-1 alleles in Norwegian lung cancer patients |
| Q40092258 | High densitiy lipoprotein (HDL) polymorphisms in rabbit: production of antibody to rabbit allotype (R 67) in sheep |
| Q39996519 | High density lipoprotein (HDL) polymorphisms in rabbit. I. A comparative study of rabbit and human serum high density lipoprotein |
| Q39386740 | High density lipoprotein (HDL) polymorphisms in rabbit. II. A study of the inherited Hl 1 and R 67 antigens in relation to HDL polypeptides |
| Q39386747 | High density lipoprotein (HDL) polymorphisms in rabbit. III. Quantitative determination of HDL and the inherited Hl 1 and R 67 antigens |
| Q35438009 | High frequency of skewed X inactivation in young breast cancer patients |
| Q34571142 | High levels of genomic aberrations in serous ovarian cancers are associated with better survival |
| Q33759046 | High prevalence of germline STK11 mutations in Hungarian Peutz-Jeghers Syndrome patients |
| Q40248027 | High-Density Lipoprotein as Carrier for Amyloid-related Protein SAA in Rabbit Serum |
| Q39470498 | High-resolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer |
| Q81094520 | High-resolution gene copy number and expression profiling of human chromosome 22 in ovarian carcinomas |
| Q34171894 | High-throughput methods for detection of genetic variation |
| Q74560121 | High-throughput screening for known mutations by automated analysis of single sequencing reactions |
| Q35024073 | High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth |
| Q67715931 | Human CYP1A1 (cytochrome P1450) gene: lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population |
| Q32164299 | Hypervariable area in the 5' flanking region of GSTP1, previously reported as a minisatellite ATAAA repeat |
| Q46945187 | Hypervariable area in the 5' flanking region of GSTP1, previously reported as a minisatellite repeat. |
| Q38332340 | Identical mutation in 55% of the ATM alleles in 11 Norwegian AT families: evidence for a founder effect |
| Q34013967 | Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers |
| Q34964405 | Identification of fusion genes in breast cancer by paired-end RNA-sequencing |
| Q48054650 | Identification of genetic variation in 11 candidate genes of canine mammary tumour |
| Q36086247 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus |
| Q46103372 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer |
| Q30587051 | Identifying in-trans process associated genes in breast cancer by integrated analysis of copy number and expression data |
| Q35104159 | Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c |
| Q96132006 | Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER positive breast cancer |
| Q61051659 | Immunohistochemical analysis of p53 protein overexpression in normal, premalignant, and malignant tissues of the cervix uteri |
| Q55449354 | Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate. |
| Q73818757 | Improved electrophoretic separation of polymorphic short tandem repeats in agarose gels using bis-benzimide |
| Q34720254 | Improving breast cancer survival analysis through competition-based multidimensional modeling |
| Q33761298 | In silico ascription of gene expression differences to tumor and stromal cells in a model to study impact on breast cancer outcome |
| Q70510508 | Increase in the ratio of serum levels of apolipoproteins A-I and A-II during prolonged physical strain and calorie deficiency |
| Q34611568 | Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study |
| Q50354104 | Independent prognostic value of somatic TP53 gene mutations in 1794 breast cancer patients. |
| Q28302352 | Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors |
| Q37592617 | Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity |
| Q41134618 | Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins |
| Q52542729 | Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. |
| Q35370090 | Insight into the heterogeneity of breast cancer through next-generation sequencing |
| Q28305345 | Integrated analysis of high-resolution DNA methylation profiles, gene expression, germline genotypes and clinical end points in breast cancer patients |
| Q35410361 | Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer |
| Q35779345 | Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling |
| Q24633201 | Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer |
| Q37728699 | Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome |
| Q73798449 | Interaction between bcl-2 and p21 (WAF1/CIP1) in breast carcinomas with wild-type p53 |
| Q53626868 | Interaction between p53 mutation and a somatic HDMX biomarker better defines metastatic potential in breast cancer. |
| Q83143293 | Interaction between p53 staining and high-dose chemotherapy in breast cancer |
| Q42366134 | Interactions between the tumor and the blood systemic response of breast cancer patients. |
| Q35633717 | International Agency for Research on Cancer workshop on 'Expression array analyses in breast cancer taxonomy' |
| Q24611474 | International network of cancer genome projects |
| Q37689772 | Interplay of choline metabolites and genes in patient-derived breast cancer xenografts |
| Q57713272 | Intra-tumor heterogeneity defines treatment-resistant HER2+ breast tumors |
| Q41497743 | Intragenic reorganization of RB1 in a complex (4;13) rearrangement demonstrated by FISH. |
| Q59132342 | Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors |
| Q24794121 | Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer |
| Q36138681 | Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas |
| Q34216309 | Ischemia caused by time to freezing induces systematic microRNA and mRNA responses in cancer tissue |
| Q41810035 | K-ras oncogene codon 12 point mutations in testicular cancer |
| Q53431648 | Ki-ras mutations and prognosis in colorectal cancer. |
| Q37228983 | LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer |
| Q34046731 | Landscape of somatic mutations in 560 breast cancer whole-genome sequences |
| Q57191573 | Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair |
| Q28267893 | Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair |
| Q67783306 | Letter: Prenatal metachromatic leukodystrophy |
| Q39387629 | Letter: Serum-H.D.L. in a therosclerotic heart-disease |
| Q33910433 | Linear and non-linear dependencies between copy number aberrations and mRNA expression reveal distinct molecular pathways in breast cancer |
| Q69914222 | Linkage disequilibrium analyses and restriction mapping of four RFLPs at the pro alpha 2(I) collagen locus: lack of correlation between linkage disequilibrium and physical distance |
| Q35980788 | Linkage disequilibrium pattern of the ATM gene in breast cancer patients and controls; association of SNPs and haplotypes to radio-sensitivity and post-lumpectomy local recurrence |
| Q35643486 | Localization of an ataxia-telangiectasia gene to an approximately 500-kb interval on chromosome 11q23.1: linkage analysis of 176 families by an international consortium |
| Q34267035 | Long non-coding RNAs differentially expressed between normal versus primary breast tumor tissues disclose converse changes to breast cancer-related protein-coding genes |
| Q69698519 | Loss of 3p or 11p alleles is associated with testicular cancer tumors |
| Q77914940 | Loss of heterozygosity at 11q23.1 and survival in breast cancer: results of a large European study. Breast Cancer Somatic Genetics Consortium |
| Q73157859 | Loss of heterozygosity at 11q23.1 in breast carcinomas: indication for involvement of a gene distal and close to ATM |
| Q72922790 | Low density lipoprotein receptor activity in cultured fibroblasts from subjects with or without ischemic heart disease (in the absence of familial hypercholesterolemia) |
| Q24796546 | Low frequency of E-cadherin alterations in familial breast cancer |
| Q35119701 | Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium |
| Q40280063 | Lp(a) phenotypes, other lipoprotein parameters, and a family history of coronary heart disease in middle-aged males |
| Q35737352 | Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53. |
| Q30489645 | Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis |
| Q46964822 | Mapping the location of recurring amplicons in array-CGH data. |
| Q69892622 | Marfan syndrome: exclusion of genetic linkage to the COL1A2 gene |
| Q44584970 | Measurement of gene activity by DNA microarrays |
| Q33748176 | Merging transcriptomics and metabolomics--advances in breast cancer profiling |
| Q37040438 | Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes |
| Q69630260 | Metachromatic leukodystrophy. I. Prenatal detection of arylsulphatase A deficiency |
| Q69605838 | Metachromatic leukodystrophy. II. Direct determination of arylsulphatase A activity in amniotic fluid |
| Q30488766 | Methylation detection oligonucleotide microarray analysis: a high-resolution method for detection of CpG island methylation |
| Q38503758 | Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer |
| Q41136238 | MicroRNA let-7b regulates genomic balance by targeting Aurora B kinase |
| Q41136545 | MicroRNA-135b regulates ERα, AR and HIF1AN and affects breast and prostate cancer cell growth |
| Q81504550 | Microarray analysis of the transcriptional response to single or multiple doses of ionizing radiation in human subcutaneous fibroblasts |
| Q34190883 | Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors |
| Q52545460 | Microarray technology--potential in cancer research |
| Q47574413 | Microarrays in primary breast cancer--lessons from chemotherapy studies |
| Q61051654 | Microsatellite instability in cervical and endometrial carcinomas |
| Q35234637 | Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes |
| Q38843629 | Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer |
| Q58348131 | Molecular Genetic Studies of Tumor suppressor Gene Regions on chromosomes 13 and 17 in Colorectal Tumors |
| Q41130424 | Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer |
| Q33892891 | Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism |
| Q71518469 | Molecular genetic changes in human male germ cell tumors |
| Q35200439 | Molecular heterogeneity in the mild autosomal dominant forms of osteogenesis imperfecta |
| Q28032461 | Molecular portraits of human breast tumours |
| Q41128277 | Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models |
| Q39061625 | Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas |
| Q46006378 | Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases. |
| Q90625531 | Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study |
| Q25256821 | Multilocus analysis of SNP and metabolic data within a given pathway |
| Q54774700 | Multiplex single-tube screening for mutations in the Nijmegen Breakage Syndrome (NBS1) gene in Hodgkin's and non-Hodgkin's lymphoma patients of Slavic origin. |
| Q50200203 | Mutagenicity testing of human milk from smokers and non-smokers in the Salmonella/microsome test. |
| Q34480997 | Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells |
| Q24302433 | Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway |
| Q46394294 | Mutant p53 exerts its gain of function through activation of the NF-κB pathway. |
| Q32028100 | Mutation analyses of KRAS exon 1 comparing three different techniques: temporal temperature gradient electrophoresis, constant denaturant capillary electrophoresis and allele specific polymerase chain reaction |
| Q34347579 | Mutation of GATA3 in human breast tumors |
| Q74582692 | Mutation screening of BRCA1 using PTT and LOH analysis at 17q21 in breast carcinomas from familial and non-familial cases |
| Q44644465 | Mutation screening of the TP53 gene by temporal temperature gel electrophoresis (TTGE). |
| Q80902048 | Mutation screening of the TP53 gene by temporal temperature gradient gel electrophoresis |
| Q24620915 | Mutational processes molding the genomes of 21 breast cancers |
| Q40143922 | Mutations and polymorphisms of the p21B transcript in breast cancer |
| Q41961782 | Mutations for the people |
| Q73341662 | Mutations in exons 5-8 of the p53 gene, independent of their type and location, are associated with increased apoptosis and mitosis in invasive breast carcinoma |
| Q52308791 | N-glycan signatures identified in tumor interstitial fluid and serum of breast cancer patients - association with tumor biology and clinical outcome. |
| Q33921638 | NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations |
| Q37421423 | Next-generation sequencing of disseminated tumor cells |
| Q41605880 | No alterations in exon 21 of the RB1 gene in sarcomas and carcinomas of the breast, colon, and lung |
| Q73100626 | No association between radiosensitivity and TP53 status, G1 arrest or protein levels of p53, myc, ras or raf in human melanoma lines |
| Q72073392 | No germline TP53 mutations detected in familial and bilateral testicular cancer |
| Q91324150 | Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics |
| Q38435494 | Nonrandom distribution of oncogene amplifications in bilateral breast carcinomas: Possible role of host factors and survival bias |
| Q35752042 | Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures |
| Q35173695 | Novel patterns of genome rearrangement and their association with survival in breast cancer |
| Q33918128 | Nuclear CSPP1 expression defined subtypes of basal-like breast cancer |
| Q72878101 | Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility |
| Q42337406 | On the molecular biology of breast cancer |
| Q53635346 | On the proposed association of the ATM variants 5557G>A and IVS38-8T>C and bilateral breast cancer. |
| Q35695175 | Oncogenesis in ovarian cancer |
| Q74218266 | Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell Non-Hodgkin's lymphoma |
| Q24798929 | Optimization and evaluation of T7 based RNA linear amplification protocols for cDNA microarray analysis |
| Q30433319 | Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study |
| Q28388563 | Overrepresentation of transcription factor families in the genesets underlying breast cancer subtypes |
| Q42373058 | P53 mutations in gastric carcinomas |
| Q43723490 | PIK3CA mutations in advanced ovarian carcinomas |
| Q38410732 | Paired distribution of molecular subtypes in bilateral breast carcinomas. |
| Q45988269 | Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors. |
| Q40152817 | Partial purification and characterization of the inherited Hl 1 and R 67 antigens of rabbit serum high density lipoprotein |
| Q64114346 | Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation |
| Q91198774 | PathTracer: High-sensitivity detection of differential pathway activity in tumours |
| Q27863385 | Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival. |
| Q92982571 | Personalized Cancer Care: Risk Prediction, Early Diagnosis, Progression, and Therapy |
| Q34608771 | Personalized cancer care conference |
| Q62583133 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes |
| Q36066735 | Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression |
| Q36385696 | Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q44443788 | Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy |
| Q68520365 | Prenatal diagnosis in a female carrying a deletion close to the Duchenne locus |
| Q69908814 | Prenatal diagnosis of glycerol-kinase deficiency associated with a DNA deletion on the short arm of the X-chromosome |
| Q72535428 | Prenatal diagnosis of homocystinuria |
| Q71350247 | Presence of "free" apoA-I in serum: implications for immunological quantification of HDL and its apoproteins |
| Q41252044 | Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer |
| Q53405631 | Primary cervical carcinomas show 2 common regions of deletion at 3P, 1 within the FHIT gene: evaluation of allelic imbalance at FHIT, RB1 and TP53 in relation to survival. |
| Q73322847 | Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome |
| Q38206642 | Principles and methods of integrative genomic analyses in cancer |
| Q38987546 | Profiling of microRNAs in tumor interstitial fluid of breast tumors - a novel resource to identify biomarkers for prognostic classification and detection of cancer |
| Q53871148 | Prognostic and predictive value of changes in tumour cell proliferation in locally advanced breast cancer primarily treated with doxorubicin. |
| Q35976693 | Prognostic significance of TP53 alterations in breast carcinoma |
| Q46013371 | Promising method for DNA extraction from paraffin embedded archive material. |
| Q46506681 | Promoter composition predicts gene classes in microarray expression analyses of breast cancer |
| Q61051647 | Protein Expression and Prognostic Value of Genes in the erb-b Signaling Pathway in Advanced Ovarian Carcinomas |
| Q81278294 | Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas |
| Q28651483 | Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines |
| Q35842801 | PstI polymorphism at the human P1450 gene on chromosome 15 |
| Q55508030 | Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. |
| Q40140887 | Purification and partial characterization of the apoA-I of rabbit high density lipoprotein |
| Q35008011 | Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors |
| Q36532093 | Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival |
| Q35204472 | Quantitative multigene FISH on breast carcinomas identifies der(1;16)(q10;p10) as an early event in luminal A tumors |
| Q34425705 | RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability |
| Q36009422 | RAD51B in Familial Breast Cancer |
| Q69897370 | RFLPs in collagen loci and disease |
| Q30432746 | Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study |
| Q53607107 | Radiation-induced effects on gene expression: an in vivo study on breast cancer. |
| Q42520837 | Radiation-induced gene expression in human subcutaneous fibroblasts is predictive of radiation-induced fibrosis |
| Q72216213 | Rare Ha-ras1 alleles and predisposition to testicular cancer |
| Q73368658 | Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients [seecomments] |
| Q73714643 | Recurrent fallopian tube carcinoma: TP53 mutation and clinical course |
| Q46945231 | Relation of gene expression-based tumor subclasses to clinical phenotypes. |
| Q73272323 | Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas |
| Q40112865 | Relationship between p53 and p27 expression following HER2 signaling |
| Q28131820 | Repeated observation of breast tumor subtypes in independent gene expression data sets |
| Q46370421 | Reply: Increased risk of breast cancer among female relatives of patients with Ataxia-Telangiectasia: a causal relationship? |
| Q114872519 | Reprogrammed transsulfuration promotes basal-like breast tumor progression via realigning cellular cysteine persulfidation |
| Q91903145 | Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain |
| Q30438623 | Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study |
| Q36134351 | Risk of cancer in relatives of testicular cancer patients. |
| Q68191892 | Role of genetic factors in breast cancer susceptibility |
| Q51062299 | SNP in TXNRD2 associated with radiation-induced fibrosis: a study of genetic variation in reactive oxygen species metabolism and signaling. |
| Q42337361 | SNPs associated with molecular subtypes of breast cancer: on the usefulness of stratified Genome-wide Association Studies (GWAS) in the identification of novel susceptibility loci |
| Q43161301 | SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance |
| Q36621619 | Screening breast cancer patients for Norwegian ATM mutations |
| Q46944925 | Screening breast cancer patients for Norwegian ATM mutations |
| Q73441573 | Screening for ESR mutations in breast and ovarian cancer patients |
| Q70484971 | Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE) |
| Q36420172 | Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families |
| Q58048756 | Screening for base mutations in the PAH and HPRT loci using the polymerase chain reaction (PCR) in combination with denaturing gradient gel electrophoresis (DGGE) |
| Q58048740 | Screening for germ line TP53 mutations in breast cancer patients |
| Q58048744 | Screening for mutations in human HPRT cDNA using the polymerase chain reaction (PCR) in combination with constant denaturant gel electrophoresis (CDGE) |
| Q73196800 | Screening of 229 family cancer patients for a germline estrogen receptor gene (ESR) base mutation |
| Q42384332 | Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy |
| Q40592492 | Serum N-glycan analysis in breast cancer patients--Relation to tumour biology and clinical outcome |
| Q42005818 | Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up |
| Q58130125 | Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab |
| Q33980589 | Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas |
| Q71623841 | Serum reserve cholesterol binding capacity (SRCBC) in familial hypercholesterolemia |
| Q49140524 | Serum reserve cholesterol binding capacity (SRCBC): the relative importance of different lipoprotein classes. |
| Q39368542 | Serum-high-density-lipoprotein and atherosclerotic heart-disease |
| Q29547191 | Signatures of mutational processes in human cancer |
| Q77590852 | Single tube multiplex polymerase chain reaction genotype analysis of GSTM1, GSTT1 and GSTP1: relation of genotypes to TP53 tumor status and clinicopathological variables in breast cancer patients |
| Q70972741 | Somatic mutations in the hMSH2 gene in microsatellite unstable colorectal carcinomas |
| Q38886065 | Somatic mutations reveal asymmetric cellular dynamics in the early human embryo |
| Q35749438 | Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas |
| Q71169983 | Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients |
| Q48925075 | Spinal muscular atrophy type I combined with atrial septal defect in three sibs. |
| Q35982667 | Studies of the L-myc DNA polymorphism and relation to metastasis in Norwegian lung cancer patients |
| Q24794680 | Study design: evaluating gene-environment interactions in the etiology of breast cancer - the WECARE study |
| Q94355969 | Subclassification and molecular characterization of early stage breast carcinomas using Applied Biosystems Human Genome Survey Microarrays |
| Q53121506 | Subtype-specific micro-RNA expression signatures in breast cancer progression. |
| Q39521987 | Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts |
| Q30566197 | Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer |
| Q35124596 | Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status |
| Q34576377 | Systems biology and genomics of breast cancer |
| Q36889861 | TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients |
| Q38999130 | TP53 Mutations in Breast and Ovarian Cancer |
| Q93123334 | TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer |
| Q42389639 | TP53 allele loss, mutations and expression in malignant melanoma |
| Q71835765 | TP53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast |
| Q77976580 | TP53 alterations in relation to the cell cycle-associated proteins p21, cyclin D1, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus |
| Q35078761 | TP53 and breast cancer |
| Q74361064 | TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival |
| Q36081911 | TP53 gene mutations and protein accumulation in primary vaginal carcinomas |
| Q44679253 | TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer |
| Q42458495 | TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance |
| Q35906287 | TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer |
| Q46559722 | TP53 mutations among molecular subtypes of HER2-positive tumors. |
| Q44964668 | TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. |
| Q61051645 | TP53 mutations and codon 72 genotype--impact on survival among ovarian cancer patients |
| Q36696616 | TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival |
| Q36777326 | TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes |
| Q24812743 | TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival |
| Q38480443 | TP53 mutations in prostatic cancer. Analysis of pre- and post-treatment archival formalin-fixed tumour tissue |
| Q81616768 | TP53 mutations in synchronous and metachronous bilateral breast carcinomas |
| Q73272333 | TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas |
| Q37661498 | The 5p12 breast cancer susceptibility locus affects MRPS30 expression in estrogen-receptor positive tumors |
| Q74812725 | The APC gene I1307K variant is rare in Norwegian patients with familial and sporadic colorectal or breast cancer |
| Q39527587 | The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma |
| Q39223582 | The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells |
| Q57743557 | The Life History of 21 Breast Cancers |
| Q47852784 | The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer |
| Q57266603 | The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians |
| Q35804614 | The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer |
| Q44258889 | The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. |
| Q35975917 | The TP53 tumour suppressor gene in colorectal carcinomas. I. Genetic alterations on chromosome 17 |
| Q35975883 | The TP53 tumour suppressor gene in colorectal carcinomas. II. Relation to DNA ploidy pattern and clinicopathological variables |
| Q41631206 | The apoE polymorphism studied by two-dimensional, high-resolution gel electrophoresis of serum |
| Q68311613 | The c-erbB-2 Protein in Primary and Metastatic Breast Carcinomas |
| Q91258149 | The circular RNome of primary breast cancer |
| Q27824864 | The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer |
| Q40140880 | The distribution of the inherited Hl 1 and R 67 antigens on rabbit serum high density lipoprotein (HDL) particles |
| Q70158449 | The effect of Gemfibrozil on human serum apolipoproteins and on serum reserve cholesterol binding capacity (SRCBC) |
| Q72401194 | The gene for apolipoprotein C-II is closely linked to the gene for apolipo-protein E on chromosome 19 |
| Q37775402 | The genetics and epigenetics of fatigue |
| Q29614700 | The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups |
| Q44203256 | The impact of an early truncating founder ATM mutation on immunoglobulins, specific antibodies and lymphocyte populations in ataxia-telangiectasia patients and their parents |
| Q46051909 | The importance of gene-centring microarray data |
| Q29614637 | The landscape of cancer genes and mutational processes in breast cancer |
| Q29614642 | The life history of 21 breast cancers |
| Q47210792 | The molecular weight of sodium hyaluronate in amniotic fluid |
| Q35332888 | The multitude of molecular analyses in cancer: the opening of Pandora’s box. |
| Q51779053 | The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer. |
| Q28275430 | The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes |
| Q37211361 | The topography of mutational processes in breast cancer genomes |
| Q37782763 | The use of gene technology in the clinical laboratory |
| Q36115202 | Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status |
| Q59800663 | Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations |
| Q92225434 | Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data |
| Q28396153 | Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing |
| Q61054245 | Tracking of fruit and vegetable consumption from childhood to adolescence: The Gateshead Millennium Study |
| Q36559648 | Transcriptional networks inferred from molecular signatures of breast cancer |
| Q40130967 | Transcriptional response to ionizing radiation in human radiation sensitive cell lines |
| Q48676100 | Transport and distribution of homocarnosine after intracerebroventricular and intravenous injection in the rat. |
| Q38126995 | Triple-negative breast cancer and the need for new therapeutic targets |
| Q37764168 | Triple-negative breast cancer: present challenges and new perspectives |
| Q52537938 | Truncating somatic mutation in exon 15 of the APC gene is a rare event in human breast carcinomas. Mutations in brief no. 179. Online. |
| Q35579053 | Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF. |
| Q35924754 | Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity. |
| Q46945482 | Two molecular cytogenetic views of breast cancer. |
| Q34531091 | Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas |
| Q30438940 | Variants in the ATM gene associated with a reduced risk of contralateral breast cancer |
| Q24816153 | Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients |
| Q47806975 | Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency |
| Q33911898 | Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma |
| Q24800356 | Workshop on The Epidemiology of the ATM Gene: Impact on Breast Cancer Risk and Treatment, Present Status and Future Focus, Lillehammer, Norway, 29 June 2002. |
| Q46944669 | X chromosome inactivation pattern in female patients with breast cancer. |
| Q74840042 | [Diagnostic molecular biology in breast cancer] |
| Q71543715 | [Early diagnosis of colorectal tumors] |
| Q70343143 | [Fabry's disease detected by renal biopsy] |
| Q69798058 | [Gene technology in clinical medicine--technics and tools] |
| Q69421515 | [Gene technology in the prevention of cancer] |
| Q74691535 | [Hereditary cancer] |
| Q74632061 | [Molecular biology. Basis for increased understanding of diseases and improved diagnostics] |
| Q74632109 | [Molecular genetic diagnostics. Technology for detecting mutations in DNA] |
| Q72841425 | [Molecular pathology. A new diagnostic dimension] |
| Q52389137 | [The 1993 Nobel Prize in chemistry--polymerase chain reaction and directed mutagenesis]. |
| Q44675424 | c-erbB-2 expression in primary gastric carcinomas and their metastases |
| Q90299179 | miR-342-5p as a Potential Regulator of HER2 Breast Cancer Cell Growth |
| Q92554251 | miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer |
| Q28742532 | miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors |
| Q46944984 | p16INK4A as a predictive factor in patients with locally advanced breast cancer treated with neoadjuvant doxorubicin monotherapy. |
| Q58048735 | p53 abnormalities in different subtypes of human sarcomas |
| Q61627327 | p53 alterations in gastric carcinoma: |
| Q72313859 | p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer |
| Q61051651 | p53 polymorphism and cervical cancer |
| Q59072739 | p53 polymorphism and risk of cervical cancer |
| Q37010494 | p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. |
| Q34187491 | Jon Dale | spouse | P26 |
| Anne-Lise Børresen-Dale | wikipedia | |
| nb | Anne-Lise Børresen-Dale | wikipedia |
Search more.